The prospect of four new cancer medicines becoming a reality for patients has taken a huge step forward with the announcement of the largest healthcare investment by a European private biotech company in over a year.
Patients with advanced cancer are already benefiting from the first of these new agents, and three more new agents will follow in the next 18-24 months.
Edinburgh based biopharmaceutical company, NuCana, has announced a new 34M investment to develop its portfolio of anti-cancer medicines based on ProTide technology.
ProTides is a platform developed by Professor Chris McGuigan and his team at Cardiff University's School of Pharmacy and Pharmaceutical Sciences. ProTides are specifically designed to bypass key cancer cell resistance pathways that limit the efficacy of so many of today's anti-cancer drugs.
The funds will be used to advance and expand the clinical programme for NuCana's lead product, Acelarin, which has shown exceptional results in patients with a broad range of advanced and progressive cancers that were resistant to all conventional therapies.
Acelarin will be developed initially for patients with pancreatic, biliary, lung and ovarian cancers. In addition, the funding means the company plans to bring a second ProTide (NUC-3373) into the clinic later this year, with two further ProTides scheduled for 2015.
"It is very exciting to watch a new medicine emerge, from a theoretical idea, through chemical synthesis in our laboratory here in Cardiff and now as a new treatment for patients with cancer" according to Professor McGuigan, who developed the ProTide technology.
"This 34M investment is extremely satisfying and an endorsement of our work with NuCana. Over the last decade this represents the 14th largest private biotech round globally and the largest ever in the UK," he added.
The financing is led by a new investor, US based venture capital firm Sofinnova V
|Contact: Chris McGuigan|